Clinical trials
for patients

El objetivo principal del presente estudio es evaluar la seguridad y la tolerabilidad de los medicamentos del estudio en un seguimiento a largo plazo.

En este estudio de investigación, se probará un nuevo producto en investigación llamado cemsidomida junto con dexametasona. La cemsidomida no ha sido aprobada por ninguna autoridad sanitaria, como la Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), la Agencia Europea de Medicamentos (European Medicines Agency, EMA), etc. para el tratamiento de ninguna enfermedad. Sin embargo, las autoridades sanitarias han permitido el uso de cemsidomida en este estudi...

El objetivo de este estudio es evaluar si la adición de revumenib a la quimioterapia estándar mejora los resultados en pacientes con leucemia mieloide aguda (LMA) con ciertas mutaciones genéticas, en comparación con la quimioterapia sola. El estudio también evaluará la seguridad de añadir revumenib a la quimioterapia.

The primary objective is to determine the recommended phase 2 dose (RP2D) of BNT323 in combination with BNT327 by evaluating safety.

This study is designed to determine whether the investigational treatment AZD9793, a GPC3-targeting T-cell engager antibody, is safe, tolerable, and has anticancer activity in patients with advanced or metastatic solid tumors that are GPC3-positive.

The main objective of this study is to assess the efficacy of a new treatment, ramantamig-D, compared with the standard treatments DVRd or DRd, in terms of progression-free survival (PFS; the time until a participant’s disease worsens) and the minimal residual disease (MRD)-negative complete response (CR) rate at 12 months (the percentage of participants in whom no cancer cells are detected) in participants with newly diagnosed multiple myeloma (NDMM; an early stage of blood cancer that de...

The purpose of this study is to determine whether the study drug, ASP3082, is safe and effective as a treatment for people with metastatic pancreatic ductal adenocarcinoma (PDAC) with a KRAS G12D mutation. The study will evaluate ASP3082 in combination with either mFOLFIRINOX (irinotecan, leucovorin [LV] [folinic acid or levofolinate], the fluoropyrimidine 5-fluorouracil [5-FU], and oxaliplatin) OR NALIRIFOX (liposomal irinotecan, LV, 5-FU, and oxaliplatin). The study team will investigate how t...

The goal of this study is to evaluate whether barzolvolimab (also known as CDX-0159) has long-term effects in keeping chronic spontaneous urticaria (CSU) under control, whether affected individuals can safely stop taking their current oral medications (e.g., antihistamines), and, in cases where CSU has worsened, whether repeating treatment with barzolvolimab can bring it back under control.

The purpose of these studies is to investigate in greater depth issues related to your condition or the study drug. The importance of these additional studies lies in the fact that they will lead to a better understanding of human health and differences in response to drugs and treatments.

The purpose of this study is to evaluate the safety of a new treatment called the FARAFLEX™ Pulsed Field Ablation (PFA) mapping and ablation system and to determine whether it is effective for the treatment of paroxysmal and persistent atrial fibrillation. The ablation that your doctor will perform as part of this study will be similar to the ablation they would perform if you were not participating in the study, except that a different system—one that has already been approved by lo...

The primary objective of this study is to evaluate the safety of the investigational drug, BMS-986340, administered as monotherapy (Part 1A and Part 2A) and in combination with nivolumab (Part 1B and Part 2B). This study will investigate how selected patients with advanced solid tumors tolerate these drugs in order to identify the highest tolerated dose or the most appropriate dose, and to assess any changes in their tumors and overall health after receiving multiple doses of BMS-986340, either ...

The purpose of this study is to test the investigational drug S241656, which is a type of anticancer drug designed to target and block various cancers that have certain types of mutations and other genetic alterations in the tumor that promote its survival and growth.

The primary objective of this study is to evaluate the effects of bempedoic acid/ezetimibe/high-intensity statins on the regression and stabilization of coronary atherosclerotic plaque in patients without serious cardiovascular events

The study aims to determine how effective the study drug is at preventing venous thromboembolism (VTE) and related conditions after total knee arthroplasty, compared with acetylsalicylic acid. VTE involves a blood clot (thrombus) that forms in a vein. Part of the clot can break off and travel through the bloodstream; this is called an embolus. If it reaches the lungs, it can cause a potentially life-threatening pulmonary embolism (PE).

The purpose of this research study is to evaluate the safety and efficacy of an investigational drug called mivelsiran (ALN-APP). This drug has not been approved by the health authorities in your country for use outside this research study. The study drug will be evaluated to determine the effects of mivelsiran in people with early-stage Down syndrome-associated Alzheimer’s disease (DS-AD). The study aims to determine: The effects of mivelsiran on the brain that can be observed using di...

The primary objective of this study is to determine whether survodutide can reduce urinary protein levels in people with overweight who already have protein loss in their urine. This could help reduce the risk of long-term kidney damage.

The purpose of this study is to evaluate the safety and efficacy of each of the three study drugs (Fx, Bv, or Rz) in reducing kidney cell damage, decreasing the amount of protein that leaks into the urine, and improving symptoms, compared with placebo (a dummy treatment containing no active drug).

This study is open to adults with advanced or metastatic solid tumors, such as non-small cell lung cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, esophageal squamous cell carcinoma, bladder cancer, vulvar cancer, and cervical cancer. Patients may participate if no standard treatment options are available to them and they have a measurable lesion outside the central nervous system. The aim of this study is to determine how well BI 3822971 is tolerated by people with...

The aim of this study is to gather further information on how cilta-cel works and its safety in the treatment of patients with multiple myeloma, a type of cancer. The study will include different groups of patients, referred to as cohorts.